Huperzine A for the treatment of cognitive, mood, and functional deficits after moderate and severe TBI (HUP-TBI): results of a Phase II randomized controlled pilot study: implications for understanding the placebo effect.

MLA

Zafonte, Ross D., et al. “Huperzine A for the Treatment of Cognitive, Mood, and Functional Deficits after Moderate and Severe TBI (HUP-TBI): Results of a Phase II Randomized Controlled Pilot Study: Implications for Understanding the Placebo Effect.” Brain Injury, vol. 34, no. 1, Jan. 2020, pp. 34–41. EBSCOhost, https://doi.org/10.1080/02699052.2019.1677941.

APA

Zafonte, R. D., Fregni, F., Bergin, M. J. G., Goldstein, R., Boudreau, N., Monge, I., Luz, M., Frazier, J., & Giacino, J. T. (2020). Huperzine A for the treatment of cognitive, mood, and functional deficits after moderate and severe TBI (HUP-TBI): results of a Phase II randomized controlled pilot study: implications for understanding the placebo effect. Brain Injury, 34(1), 34–41. https://doi.org/10.1080/02699052.2019.1677941

Chicago

Zafonte, Ross D., Felipe Fregni, Michael J.G. Bergin, Richard Goldstein, Nancy Boudreau, Iris Monge, Matthew Luz, Judith Frazier, and Joseph T. Giacino. 2020. “Huperzine A for the Treatment of Cognitive, Mood, and Functional Deficits after Moderate and Severe TBI (HUP-TBI): Results of a Phase II Randomized Controlled Pilot Study: Implications for Understanding the Placebo Effect.” Brain Injury 34 (1): 34–41. doi:10.1080/02699052.2019.1677941.